TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1751367

Group type: EXPERIMENTAL
Intervention: Sudan Black positivity (SB positivity)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Low complement of maturing granulocytes
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: High percentage of blasts
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Acute promyelocytic leukaemia (FAB M3)
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Multiple lineage leukaemias with megakaryocytic and/or erythroid involvement
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: Percentage SB positivity
Number of subjects: 1386

Group type: EXPERIMENTAL
Intervention: SB positivity
Number of subjects: 1386
Study: 7038076

Group type: EXPERIMENTAL
Intervention: Exchange transfusion
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Administration of fresh-frozen plasma and platelets
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control (no therapy directed specifically at the coagulopathy)
Number of subjects: 33
Study: 31935272

Group type: EXPERIMENTAL
Intervention: Food insecurity (mild, moderate, severe)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Lower dietary diversity
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Unemployment of participants or spouses
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Owning cultivable land
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Participants' unemployment status
Number of subjects: 417
Study: 30909877

Group type: EXPERIMENTAL
Intervention: Temperature at +22 °C with brisk walking for 30 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Temperature at -15 °C with brisk walking for 30 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Temperature at +22 °C at rest for 30 min
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Temperature at -15 °C at rest for 30 min
Number of subjects: 18
Study: 29084597

Group type: EXPERIMENTAL
Intervention: Virtual community of practice for primary healthcare professionals for 12 months
Number of subjects: 270

Group type: COMPARATOR
Intervention: Usual training
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Virtual community of practice
Number of subjects: 270
Study: 24756025

Group type: EXPERIMENTAL
Intervention: BCI-Manus therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Manus therapy
Number of subjects: 26
Study: 24245880

Group type: EXPERIMENTAL
Intervention: Restylane Vital® with NAHSA injector
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 10
Study: 22955227

Group type: EXPERIMENTAL
Intervention: Late CNI withdrawal
Number of subjects: 108

Group type: COMPARATOR
Intervention: MMF withdrawal
Number of subjects: 108
Study: 19838098

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 88

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study: 17624196

Group type: EXPERIMENTAL
Intervention: Etoricoxib (90 mg, tablet)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 16317669

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 1 g/day for three weeks
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg/day for 1 week and placebo during weeks 2 and 3
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 130
Study: 14569803

Group type: EXPERIMENTAL
Intervention: ASCUS management strategies
Number of subjects: 2000000

Group type: EXPERIMENTAL
Intervention: Bethesda System 2001 Workshop recommendations
Number of subjects: 2000000
Study: 9593551

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 0
Study: 7645522

Group type: EXPERIMENTAL
Intervention: Diltiazem plus trimetazidine (diltiazem 60 mg three times daily and trimetazidine 20 mg three times daily)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Diltiazem plus placebo
Number of subjects: 67
Study: 2142741

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (tissue plasminogen activator)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (streptokinase)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combined trials of intravenous thrombolysis
Number of subjects: 7

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 7
Study: 277563

Group type: EXPERIMENTAL
Intervention: Mini-lecture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Role-playing
Number of subjects: 12
Study: 31100455

Group type: EXPERIMENTAL
Intervention: EPIT with Viaskin milk
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: EPIT with Viaskin milk (open-label phase)
Number of subjects: 20
Study: 31201564

Group type: EXPERIMENTAL
Intervention: Ultrasound measuring system
Number of subjects: 31
Study: 28891839

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 44
Study: 25647646

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT) - 3-8 sprints at maximal intensity, 3 times a week for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23339726

Group type: EXPERIMENTAL
Intervention: Combination aliskiren/valsartan 150/160 mg
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Valsartan 160 mg monotherapy
Number of subjects: 1143

Group type: EXPERIMENTAL
Intervention: Combination aliskiren/valsartan
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 1143
Study: 21401585

Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bimanual training (BIM)
Number of subjects: 63
Study: 18492286

Group type: EXPERIMENTAL
Intervention: Group A (provided with additional information regarding the risks of TCS)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Group B (not provided with additional risk information)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Risk information provision
Number of subjects: 285
Study: 16804292

Group type: EXPERIMENTAL
Intervention: Ketoconazole 100 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no ketoconazole)
Number of subjects: 70
Study: 12702104

Group type: EXPERIMENTAL
Intervention: GTR + Bio‐Oss (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: GTR treatment alone (control)
Number of subjects: 18
Study: 10985713

Group type: EXPERIMENTAL
Intervention: Surgical repair (31 patients with rupture, 21 had concomitant bypass surgery)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Medical management (24 patients managed medically)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: In-hospital mortality for patients with VSR
Number of subjects: 939

Group type: COMPARATOR
Intervention: In-hospital mortality for patients without VSR (control group)
Number of subjects: 939
Study: 8623953

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1306817

Group type: EXPERIMENTAL
Intervention: Nifedipine (N group)
Number of subjects: 1666

Group type: COMPARATOR
Intervention: Placebo (P group)
Number of subjects: 1666
Study: 3935313

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (5 mg delivered over 24 hours, applied every 48 hours)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin
Number of subjects: 25
Study: 30041639

Group type: EXPERIMENTAL
Intervention: Rango Cards, a digital game designed to promote healthy dietary practices.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 0
Study: 27263310

Group type: EXPERIMENTAL
Intervention: 10 mL normal saline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 15 mL normal saline
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0 mL normal saline (control group)
Number of subjects: 80
Study: 24867930

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 1.09% Gromega
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 0.07% zinc sulfate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet supplemented with both Gromega and zinc sulfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 0
Study: 22233397

Group type: EXPERIMENTAL
Intervention: Noninvasive cortical electrostimulation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 20381003

Group type: EXPERIMENTAL
Intervention: Medial wedge
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lateral wedge
Number of subjects: 38

Group type: COMPARATOR
Intervention: Baseline control
Number of subjects: 38
Study: 18322263

Group type: EXPERIMENTAL
Intervention: Galantamine (16-24 mg/day)
Number of subjects: 2048

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2048
Study: 15867860

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPNDs)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPNDs) and Placebo
Number of subjects: 54
Study: 15519702

Group type: EXPERIMENTAL
Intervention: DTPa/Hib (PRP-T) booster dose
Number of subjects: 368

Group type: COMPARATOR
Intervention: Unconjugated PRP (PRP) challenge dose plus separate DTPa vaccine
Number of subjects: 368
Study: 11356400

Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy or other pharmacologic therapy started before discharge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic treatment plans for management of risk factors after hospitalization
Number of subjects: 0
Study: 9244213

Group type: EXPERIMENTAL
Intervention: Combined antiplatelet therapy (aspirin plus ticlopidine)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Conventional anticoagulant therapy (phenprocoumon with initial overlapping heparin plus aspirin)
Number of subjects: 496
Study: 8274324

Group type: EXPERIMENTAL
Intervention: 2% lignocaine with 1:80,000 adrenaline
Number of subjects: 43

Group type: COMPARATOR
Intervention: 1.5% etidocaine with 1:200,000 adrenaline
Number of subjects: 43
Study: 3488978

Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate and sulfisoxizole
Number of subjects: 137

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 137
Study: 30326126

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (76% Roux-en-Y gastric bypass, 17% sleeve gastrectomy, 7% adjustable gastric banding)
Number of subjects: 5301

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 5301
Study: 25892603

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (6000 IU/day for 3 months, then 3000 IU/day for 3 months, followed by 2200 IU/day for 6 months)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 25487763

Group type: EXPERIMENTAL
Intervention: Patient education program
Number of subjects: 395

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 395
Study: 23270285

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite (SH)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine digluconate (CHX)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 0.1% octenidine dihydrochloride (OCT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline solution (SS)
Number of subjects: 70
Study: 20544405

Group type: EXPERIMENTAL
Intervention: Patient self-management intervention delivered by a nurse, six contacts over 8 weeks.
Number of subjects: 333
Study: 19265635

Group type: EXPERIMENTAL
Intervention: Combination therapies with second-generation antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) combined with lithium or divalproex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine plus fluoxetine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quetiapine combined with lithium or valproate
Number of subjects: 0
Study: 15935266

Group type: EXPERIMENTAL
Intervention: APF foam
Number of subjects: 661

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: APF gel
Number of subjects: 661
Study: 12529459

Group type: EXPERIMENTAL
Intervention: Ultrasonogram
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Initial renal scan
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Voiding cystourethrogram
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Repeated renal scans
Number of subjects: 309
Study: 10730801

Group type: EXPERIMENTAL
Intervention: Active educational intervention focused on breast cancer early detection
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive educational intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Active educational intervention
Number of subjects: 8
Study: 9273231

Group type: EXPERIMENTAL
Intervention: Jejunum and large intestine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ileum and caecum
Number of subjects: 3

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 3
Study: 1293272

Group type: EXPERIMENTAL
Intervention: Intra amniotic thyroxine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intra muscular Dexamethasone
Number of subjects: 82
Study: 3883938

Group type: EXPERIMENTAL
Intervention: Cognitive therapy alone (n = 18)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus amitriptyline hydrochloride (n = 15)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combined treatment at one-year follow-up
Number of subjects: 33
Study: 30953605

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), 3 sessions per week
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), adjusted for infant birth weight
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Aquatic physical exercise program (SWEP method), for women with previous births
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (routine prenatal care only)
Number of subjects: 129
Study: 29273308

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT) with carboplatin and paclitaxel (CT) followed by interval cytoreductive surgery and then 3 additional cycles of CT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Primary cytoreductive surgery (PCS) followed by 6 cycles of CT
Number of subjects: 0
Study: 27447802

Group type: EXPERIMENTAL
Intervention: 40 mg oral prednisolone
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 40 mg submucosal injection of prednisolone
Number of subjects: 186

Group type: COMPARATOR
Intervention: No prednisolone (control group)
Number of subjects: 186
Study: 24966145

Group type: EXPERIMENTAL
Intervention: Facial reanimation surgery
Number of subjects: 86

Group type: COMPARATOR
Intervention: Paralyzed faces
Number of subjects: 86

Group type: COMPARATOR
Intervention: Normal faces
Number of subjects: 86
Study: 22494856

Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil/salicylic acid (5-FU/SA)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 175

Group type: COMPARATOR
Intervention: 3% diclofenac/hyaluronic acid (HA)
Number of subjects: 175
Study: 20236216

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES) in MB-stent group
Number of subjects: 100
Study: 17916949

Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite 0.2 mg kg‐1 day‐1 for 30 days in addition to standard chemotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 50
Study: 15613422

Group type: EXPERIMENTAL
Intervention: Flaxseed (40 g/d)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Flaxseed
Number of subjects: 199

Group type: COMPARATOR
Intervention: Wheat germ placebo
Number of subjects: 199
Study: 11797655

Group type: COMPARATOR
Intervention: Bed Rest
Number of subjects: 250

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Continuation of ADLs (Control)
Number of subjects: 250
Study: 10404946

Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 33

Group type: COMPARATOR
Intervention: Caffeine (in hot water)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Green tea (regular consumption)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Black tea (regular consumption)
Number of subjects: 33
Study: 7770605

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation (ten times the recommended daily dose of nine vitamins)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study: 2139769

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg/day during the luteal phase
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 26
Study: 111085

Group type: EXPERIMENTAL
Intervention: Hepavis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alcohol abstinence alone (Control)
Number of subjects: 30
Study: 30859640

Group type: EXPERIMENTAL
Intervention: Transfusion at a higher platelet count threshold (< 50 x 10^9/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion only when platelet count drops below 25 x 10^9/L
Number of subjects: 0
Study: 28472315

Group type: EXPERIMENTAL
Intervention: PhysRx (physiologically individualized care)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 105
Study: 25091846

Group type: EXPERIMENTAL
Intervention: Preoperative quality of life score <50
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Early complications (yes/no)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Early complications
Number of subjects: 431
Study: 24028414

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Partial or Unicompartmental Knee Replacement (UKR)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Complications data
Number of subjects: 500
Study: 21835378

Group type: EXPERIMENTAL
Intervention: OU‐CMR (stress cardiac magnetic resonance observation unit testing)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: OU‐CMR
Number of subjects: 109
Study: 19608828

Group type: EXPERIMENTAL
Intervention: Hamstring stretch position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional sitting position
Number of subjects: 0
Study: 17355546

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ergotamine 2 mg plus caffeine 200 mg
Number of subjects: 0
Study: 14731312

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11505964

Group type: EXPERIMENTAL
Intervention: Colgate Total Toothpaste (0.3% triclosan and 2% copolymer in a 0.243% sodium fluoride/silica base)
Number of subjects: 3392

Group type: COMPARATOR
Intervention: Crest Cavity Fighting Toothpaste with Fluoristat (0.243% sodium fluoride in a silica base)
Number of subjects: 3392
Study: 11764125

Group type: EXPERIMENTAL
Intervention: Proximal vertical slot resin‐based composite (RBC) restorations
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ceramic inserts with low‐viscosity resin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: RBC with low‐viscosity resin liner
Number of subjects: 90
Study: 8572352

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 423
Study: 1365474

Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (N)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Standard piroxicam (P)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Indomethacin S.R. (I)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Diclofenac S.R. (D)
Number of subjects: 96
Study: 6962709

Group type: EXPERIMENTAL
Intervention: Slow release oxprenolol (160-320 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Combination therapy (oxprenolol and chlorthalidone, and hydrallazine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30477309

Group type: EXPERIMENTAL
Intervention: EDS‐FLU 93 µg, 186 µg, or 372 µg
Number of subjects: 323

Group type: COMPARATOR
Intervention: EDS‐placebo
Number of subjects: 323
Study: 29450524

Group type: EXPERIMENTAL
Intervention: Quality improvement tool kit (n=11,308 participants)
Number of subjects: 21374

Group type: COMPARATOR
Intervention: Usual care (control group; n=10,066 participants)
Number of subjects: 21374

Group type: EXPERIMENTAL
Intervention: Quality improvement tool kit
Number of subjects: 21374

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21374
Study: 26194251

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) laparoscopy
Number of subjects: 20

Group type: COMPARATOR
Intervention: White-light laparoscopy
Number of subjects: 20
Study: 24323628

Group type: EXPERIMENTAL
Intervention: Questionnaire intervention including free text fields for goal formulation
Number of subjects: 2782

Group type: EXPERIMENTAL
Intervention: Questionnaire intervention
Number of subjects: 2782
Study: 22837094

Group type: EXPERIMENTAL
Intervention: 60 μg V710 (with or without adjuvant)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: 90 μg V710 (with adjuvant)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 19639497

Group type: EXPERIMENTAL
Intervention: Adolescents with PCOS
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study: 17667497

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LAP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional (open) Nissen fundoplication
Number of subjects: 110
Study: 16254902

Group type: EXPERIMENTAL
Intervention: Progressive strength training program (3 sessions/week for 14 weeks, intensity from 50% to 80% of 1RM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20